- Home
- NVA vs SAVA Comparison
NVA vs SAVA Comparison
Compare NVA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- SAVA
- Stock Information
- Founded
- NVA 1987
- SAVA 1998
- Country
- NVA Australia
- SAVA United States
- Employees
- NVA N/A
- SAVA N/A
- Industry
- NVA
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- NVA
- SAVA Health Care
- Exchange
- NVA NYSE
- SAVA Nasdaq
- Market Cap
- NVA 65.4M
- SAVA 70.5M
- IPO Year
- NVA N/A
- SAVA N/A
- Fundamental
- Price
- NVA $12.56
- SAVA $1.83
- Analyst Decision
- NVA
- SAVA Buy
- Analyst Count
- NVA 0
- SAVA 3
- Target Price
- NVA N/A
- SAVA $54.50
- AVG Volume (30 Days)
- NVA 15.8K
- SAVA 1.0M
- Earning Date
- NVA 01-01-0001
- SAVA 08-07-2025
- Dividend Yield
- NVA N/A
- SAVA N/A
- EPS Growth
- NVA N/A
- SAVA N/A
- EPS
- NVA N/A
- SAVA N/A
- Revenue
- NVA N/A
- SAVA N/A
- Revenue This Year
- NVA N/A
- SAVA N/A
- Revenue Next Year
- NVA N/A
- SAVA N/A
- P/E Ratio
- NVA N/A
- SAVA N/A
- Revenue Growth
- NVA N/A
- SAVA N/A
- 52 Week Low
- NVA $4.35
- SAVA $1.15
- 52 Week High
- NVA $19.00
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- SAVA 38.29
- Support Level
- NVA N/A
- SAVA $1.85
- Resistance Level
- NVA N/A
- SAVA $2.17
- Average True Range (ATR)
- NVA 0.00
- SAVA 0.10
- MACD
- NVA 0.00
- SAVA -0.04
- Stochastic Oscillator
- NVA 0.00
- SAVA 2.22
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.